Objective: Demonstrate the safety and effectiveness of palatal foreshortening and stiffening in reducing snoring severity in nonobstructive sleep apnea (non-OSA) patients complaining of chronic disruptive snoring. Results: Mean baseline bed/sleep partner VAS was 7.81 ± 1.59. Mean postimplant VAS scores decreased significantly at each measured interval; to 5.77±2.35 (P < .001) at 30 days, 4.48 ± 1.81 (P < .001) at 90 days, and 5.40 ± 2.28 (P < .001) at 180 days.
frequent in adults, males, in the overweight and usually worsens with age. Often, snoring is glossed over as an entity and attention diverts to its relationship to obstructive sleep apnea (OSA). However, snoring can have significant bothersome, if not serious consequences to the individual and to others sharing a common sleeping space. Snoring disrupts sleep and may lead to excessive daytime sleepiness and decreases in performance and productivity, lack of concentration, irritability, and decreased libido. [2] [3] [4] [5] Night-time snoring almost certainly disrupts the sleep of those in close proximity, leading to similar consequences of sleep deprivation, as well as the associated social discord and even estrangement. [6] [7] [8] [9] Whether primary or related to OSA, snoring is the result of vibration of oro-and/or nasopharynx tissue caused by turbulent airflow through the relaxed airway during sleep. Thus, virtually all current treatments involve methods to open the airway. Life-style modifications include weight loss, smoking cessation, limiting alcohol consumption, and improved sleep hygiene. [10] [11] [12] Over-the-counter treatment options include nasal sprays, nasal strips or dilators, lubricating sprays, and "anti-snore" clothing and pillows. Surgical correction is usually reserved for patients with associated moderate to severe OSA. Nonsurgical snoring treatment often focuses on palate stiffening. Methods include injection sclerotherapy, laser therapy, cautery procedures, radiofrequency ablation and palatal implants. [13] [14] [15] [16] [17] [18] [19] These procedures usually result in palatal stiffening without significant palatal shortening and all have met limited success in selected patients. To improve success rate and reduce morbidity, an office-based procedure that would both stiffen and foreshorten the palate was tested. The Elevoplasty procedure demonstrated effectiveness and safety in a single-center pilot study employing a prototype device. 20 Based on these results a multicenter, prospective study was designed for the United States. The safety endpoint was assessed by documenting and analysis of all adverse events (AEs) that occurred during the trial. The primary efficacy endpoint was the mean within-subject change of snoring visual analog scale (VAS) from baseline (prior to implant) to Day 30 postimplant as completed by the study subject's bed/sleep partner.
There were multiple secondary endpoints as noted in Table 1 ranked in order of relevance to the study.
| Selection or screening
Prospective subjects presented to the study centers with complaints of chronic, disruptive snoring and negative screening for OSA. Subjects deemed qualified to participate were informed about the trial, the proposed implant procedure and follow-up requirements and provided with IRB-approved reading material and copies of the informed consent forms for both subject and bed/sleep partner. Identified prospective subjects (and their bed/sleep partners) were invited to a baseline visit where full informed consent was provided and informed consent forms were signed, and inclusion/exclusion criteria (Table 2) were reviewed.
At enrollment, investigators documented demography, medical and surgical history, and performed a physical examination-including awake fiberoptic nasopharyngeal, hypopharyngeal endoscopy and oral cavity examinations to rule out any pathology and to identify Friedman tongue position (FTP) and tonsil size. Finally, each subject was provided with and trained to use a home sleep test (HST) device. The HST device was sent home with the understanding that the subject would self-conduct a two-night HST and return the device for data analysis. This HST functioned to confirm the presence of chronic, disruptive snoring and rule out moderate/severe OSA (apnea/hypopnea index >15). Following confirmation of both snoring and negative OSA status, the subject and bed/sleep partner received individual e-mails inviting them to complete online baseline questionnaires. The bed/sleep partner rated the subject's snoring severity (via 0-10 VAS). The subject assessed daytime somnolence via the Epworth Sleepiness Index (ESS) and sleep quality via the Pittsburgh Sleep Quality Index (PSQI). In addition, the subject was scheduled for the Elevoplasty procedure.
| Elevoplasty procedure
Each subject was treated with an in-office Elevoplasty procedure whereby three, fully resorbable (polydioxanone), barbed suture implants Once all implants were placed, the black silk sutures protruding from the subject's palate were each manually retracted causing a mild tissue apposition ("accordion-ing") of the soft palate tissue (Figure 3 ). This action was meant to slightly raise, shorten, and stiffen the soft palate, with the proximal barb row engaging with tissue to gently ratchet tension. After an approximately 1 to 4 mm of soft palate lift was achieved, the silk sutures were cut and withdrawn.
On the following day, subjects were contacted via telephone/text message to query postprocedure complications, pain, and pain medication usage. Subjects were scheduled to return in 1 month (or earlier if necessary) for a standard postprocedure follow-up.
| Data collection
Prior to the procedure, each subject and bed/sleep partner were trained on the use of an online outcomes-tracking database (Trials.ai, San Diego, California). Online questionnaire assessments were
prompted by e-mails to both the subject and the bed/sleep partner at the following four intervals: (a) before the procedure (baseline), Since inclusion criteria did not restrict enrollment to patients with a predominance of a specific snoring type, the study assessed the preand post-treatment measures to detect a change in palatal snoring vs other breathing sounds. In total, the endpoints the trial consisted of 1 primary endpoint and 14 secondary endpoints (Table 1) .
| Statistical analysis
Sample size was selected based on the potential of the lower bound of a two-sided 95% confidence interval to exceed 50%, if the patient selection criteria were appropriate. Given that no p redetermined multiple comparison rule was defined a priori, all probability values
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| RESULTS
Fifty-two study subjects were treated across seven of the eight centers that gained IRB approval to enroll subjects. Enrollment included 33 males, 19 females, and their bed/sleep partners.
Prior to treatment (baseline), the subject's mean VAS score for snoring severity as assessed by the bed/sleep partner was 7.81 ± 1.59. Safety outcomes from the trial indicate low risk of harm to patients.
There were no reported adverse events. Two subjects reported being able to palpate an implant with their tongues after discharge. In both those cases, an extruding section of the implant was discovered and treated with a simple trimming of the protruding portion of the implant in a brief follow-up office visit. This trimming with scissors involved no anesthesia, bleeding, or pain.
All subjects were contacted on the evening of postprocedure day 1 to elicit peak pain VAS on both the evening of procedure and on postprocedure day 1. Peak postprocedure pain VAS, collected on the evening of the procedure was as reported on a 0 to 10 VAS was 3.85 ± 2.69 and. 24 hours later (postprocedure day 1) was 2.90 ± 2.21.
Only 3 out of 52 (5.8%) reported using an opioid for postprocedure pain control on the evening of or day after the procedure.
| DISCUSSION
The present study was conducted in selected adult patients suffering from chronic, disruptive snoring based on their bed/sleep partner reporting, the subject's own assessment of sleep quality and confirmed by HST snoring sound recordings. Snoring is often linked to OSA and admittedly, the anatomic causes of snoring may also contribute to the OSA syndrome. However, the airway obstruction in OSA is often multilevel in origin. Since the focus of this study dealt with treatment of snoring at the level of the soft palate, patients with coexisting moderate to severe OSA were specifically excluded to more clearly discern any improvement in sleep quality without the background of OSA. The objectives of the other inclusion and exclusion criteria (Table 2) were similarly aimed to recruit those patients who could potentially most benefit from palatal stiffening and in whom demonstrable clinical improvement might be clearly recognizable.
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The results of the multi-institutional trial demonstrated a statistically significant and prolonged decrease in mean snoring severity VAS as assessed by the bed/sleep partner and thus, confirmed the prospectively-defined primary and several secondary endpoints. The mean decrease at the 30-day interval was 25% and decreasing further still to an approximately 30% at 90-and 180-days post treatment. In addition, significant and prolonged improvements in subject-reported T A B L E 3 Data summary of primary and secondary study outcome measures A study successfully treated patients undergoing initial Pillar procedure for snoring reduction results and returning to their clinic dissatisfied with a fourth or fifth additional implant to improve outcome. 27 These results might support the reasonable assumption that additional Elevo implants may further improve upon the current study's outcome.
The Elevo suture implant is comprised of polydioxanone. Testing of such resorbable suture material has shown that by 6 weeks following implantation, a significant percentage of the original tensile strength is lost. 28 Notably, the duration of snoring severity reduction appears to exceed the resorption time of implants. This observation is consistent with the notion that the physical tissue apposition of the tissue caused by the pulling of the implant induces a secondary tissue remodeling and contraction process that persists after the implant has been replaced by scar tissue. Similar rational exists for other palatal stiffening such as radiofrequency ablation of the soft palate/volumetric reduction of the tongue base (RFTBR), cautery assisted palatal stiffening procedure (CAPSO), injection sclerotherapy (injection snoreplasty) and observation of persistent snoring reduction following extrusion or removal of Pillar implants.
The overall safety of the device is characterized by the fact that there were only two reported minor adverse events. On follow-up, some subjects were able to palpate the implant following sensory recovery from the local anesthesia, this strange feeling diminished over the next 24 hours. Two subjects required a return to office for partial extrusion of the implant. Partial extrusion was treated by simply cutting away the extruded segment. There were no complete extrusions. In addition, postprocedure pain was very minor in level and short in duration. No pain medication usage was specifically directed at postprocedure pain was reported after postprocedure day 1.
| CONCLUSIONS
Based on the results of the current study, we believe that this minimally invasive office procedure can be a safe tool in treating patients suffering from predominantly palatal snoring. The limited data on our selected group of patients indicates a moderate reduction in snoring.
